| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Feb―01 |
Evaluation of the causal effects of perfluorooctanesulfonate on COVID-19 and its associated mechanisms: Integrated Mendelian randomization and network toxicology analyses |
Wenting Tao, Liang Chen |
| 2 |
[GO] |
2024―Sep―02 |
P15-15 Unveiling the therapeutic potential of MSC-derived conditioned media and exosomes towards COVID-19-induced neurological sequelae |
C.M. Trigo, S.P. Camões, A.S. Serras, A.T. Matos, R. Vitorino, A.R. Vaz, et al. (+3) D. Brites, S. Solá, J.P. Miranda |
| 3 |
[GO] |
2024―Sep―02 |
P17-05 The T cell response to SARS-CoV-2 mRNA vaccine in adults with high exposure to perfluoroalkyl substances from Ronneby, Sweden |
A. Andersson, A. Lundgren, Y. Xu, C. Nielsen, C. Lindh, D. Pineda, et al. (+6) J. Vallin, C. Johnsson, T. Fletcher, M. Bemark, K. Jakobsson, Y. Li |
| 4 |
[GO] |
2024―Sep―02 |
P21-34 SARS-CoV-2 omicron infection aggravates lung fibrosis through IL6/ CSF/ RANTES activation and dysfunction of lipid metabolism in mice with PHMG-induced lung injury |
S. Jeon, Y.K. Kim, J.-H. Hwang, M.-S. Kim |
| 5 |
[GO] |
2024―Sep―02 |
P16-02 Subchronic intramuscular toxicity and immunogenicity study of a plant-based SARS-CoV-2 vaccine in Sprague-Dawley rats with a 4-week recovery period |
S.-J. Park, E.Y. Koo, H. Park, S.E. Min, B.-H. Choi, N. Kim, et al. (+3) M.S. Jang, B.-S. Lee, Y.-B. Kim |
| 6 |
[GO] |
2024―Jun―24 |
Epidemiological Samplings for long-term HBM-studies during a pandemic situation - Experiences and lessons-learned, the German Environmental Specimen Bank during the COVID-19 pandemic |
Martina Bartel-Steinbach, Till Weber, Markus Michel, Sylvia Wagner, Heiko Zimmermann, Marike Kolossa-Gehring, Dominik Lermen |
| 7 |
[GO] |
2023―Sep―06 |
P21-16: Preconditioning MSCs with IFN-γ as a promising therapeutic strategy towards COVID-19-induced neurological damage |
C.M. Trigo, S.P. Camões, A.S. Serras, M. Gava, R. Vitorino, A.R. Vaz, et al. (+3) D. Brites, S. Solá, J.P. Miranda |
| 8 |
[GO] |
2023―Sep―06 |
P17-31: Acute exposure to urban air ultrafine and coarse particles alters cellular response to SARS-CoV-2 infection in human olfactory mucosa cells from individuals with Alzheimer's disease |
M.A. Shahbaz, L. Mussalo, S. Kuivanen, J. Kalapudas, A.M. Koivisto, E. Penttilä, et al. (+7) H. Löppönen, G. Balistreri, S. Chew, P. Jalava, O. Vapalahti, R. Lampinen, K.M. Kanninen |
| 9 |
[GO] |
2022―Sep―12 |
P03-06 The effectiveness of herbal combination as complementary treatment process in a patient with COVID-19 |
A. Ebadollahinatanzi, G. Arabrahmatipour |
| 10 |
[GO] |
2022―Sep―12 |
P22-10 Prevalence and outcome of Covid-19 in patients with substance abuse disorder presented to tertiary care hospital emergency department |
S.A. AlAbri, F. Al Majrafi |
| 11 |
[GO] |
2022―Sep―12 |
S-11-03 Accelerated timelines for non-clinical studies to support COVID-19 vaccine (AZD1222, ChAdOx1-nCov19) |
R. Stebbings |
| 12 |
[GO] |
2022―Sep―12 |
S-11-02 Regulatory considerations for non-clinical studies for COVID-19 vaccines: US FDA perspective |
C. Wrzesinski |
| 13 |
[GO] |
2022―Sep―12 |
P03-22 Evaluation of surgical stress impact over immune response against SARS-CoV-2. A pilot study |
T.K. Nikolouzakis, E. Vakonaki, M. Tzatzarakis, K. Lasithiotakis, E. Chryssos, A. Tsatsakis |
| 14 |
[GO] |
2021―Sep―24 |
Virus Response Measures in Case of Infection with a Previously Unknown Virus or COVID-19 in Employees at Research Facility |
T. Anzai, T. Matsuyama |
| 15 |
[GO] |
2021―Sep―24 |
COVID-19, health recovery by medicinal plants (health solutions): An overview |
A. Ebadollahinatanzi, G. Arabrahmatipour, M. Abedi |
| 16 |
[GO] |
2021―Sep―24 |
Specific treatments in the critically ill COVID-19 patients: benefits and toxicities |
B. Mégarbane |
| 17 |
[GO] |
2021―Sep―24 |
Rapid Development of the FDA ACMT COVID-19 ToxIC (FACT) Pharmacovigilance Pilot Project to Monitor Adverse Events Reported in Association with COVID-19 Therapeutics |
P.M. Wax, K. Aldy, J. Brent |
| 18 |
[GO] |
2021―Sep―24 |
Brain Organoids to Study SARS-Cov-2 Infection of Developing CNS |
L. Smirnova, C.K. Bullen, H.T. Hogberg, A. Pekosz, W Bishai, T. Hartung |
| 19 |
[GO] |
2021―Sep―24 |
mRNA vaccines against SARS-CoV-2: review of non-clinical challenge studies and potential contagiosity in Non Human Primates |
M. Burbank, F. D’herbe, R. Soares, G. Louin, A. Richard, V. Salomon |
| 20 |
[GO] |
2021―Sep―24 |
Assessment of the skin sensitizing potential of pandemic-associated medical devices using the GARDskin Medical Device assay |
P. Mohlin, A. Forreryd, O. Larne, R.-M. Jenvert, H. Johansson |
